Document Detail

Mean and maximum standardized uptake values in [18F]FDG-PET for assessment of histopathological response in oesophageal squamous cell carcinoma or adenocarcinoma after radiochemotherapy.
MedLine Citation:
PMID:  19096843     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To evaluate the potential of [(18)F]fluorodeoxyglucose positron emission tomography (FDG-PET) for the assessment of histopathological response and survival after neoadjuvant radiochemotherapy in patients with oesophageal cancer. PATIENTS AND METHODS: In 2005 and 2006, 55 patients (43 men, 12 women; median age 60 years) with locally advanced oesophageal cancer (cT3-4 Nx M0; 24 with squamous cell carcinoma, 31 with adenocarcinoma) underwent transthoracic en bloc oesophagectomy after completion of treatment with cisplatin, 5-fluorouracil, and radiotherapy ad 36 Gy in a prospective clinical trial. Of the 55 patients, 21 (38%) were classified as histopathological responders (<10% vital residual tumour cells) and 34 (62%) as nonresponders. FDG-PET was performed before (PET 1) and 3-4 weeks after the end (PET 2) of radiochemotherapy with assessment of maximum and average standardized uptake values (SUV) for correlation with histopathological response and survival. RESULTS: Histopathological responders had a slightly higher baseline SUV than nonresponders (p<0.0001 between PET 1 and PET 2 for responders and nonresponders) and the decrease was more prominent in responders. Except for SUVmax in patients with squamous cell carcinoma neither baseline nor preoperative SUV nor percent SUV reduction correlated significantly with histopathological response. Histopathological responders had a 2-year overall survival of 91 +/- 9% and nonresponders a survival of 53 +/- 10% (p = 0.007). CONCLUSION: Our study does not support recent reports that FDG-PET predicts histopathological response and survival in patients with locally advanced oesophageal cancer treated by neoadjuvant radiochemotherapy.
Matthias Schmidt; Elfriede Bollschweiler; Markus Dietlein; Stefan P Mönig; Carsten Kobe; Daniel Vallböhmer; Daniel Vallboehmer; Wolfgang Eschner; Arnulf Hölscher; Harald Schicha
Related Documents :
12580533 - Mechanism of cartilage destruction in osteoarthritis.
10849543 - A study of the association between the prognosis of carcinoma of the mandibular gingiva...
679163 - Liposarcoma of the neck: a clinicopathologic study of 4 cases.
Publication Detail:
Type:  Journal Article     Date:  2008-12-19
Journal Detail:
Title:  European journal of nuclear medicine and molecular imaging     Volume:  36     ISSN:  1619-7089     ISO Abbreviation:  Eur. J. Nucl. Med. Mol. Imaging     Publication Date:  2009 May 
Date Detail:
Created Date:  2009-04-10     Completed Date:  2009-08-11     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101140988     Medline TA:  Eur J Nucl Med Mol Imaging     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  735-44     Citation Subset:  IM    
Department of Nuclear Medicine, University of Cologne, Cologne, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adenocarcinoma / diagnosis,  pathology*
Carcinoma, Squamous Cell / diagnosis,  pathology*
Combined Modality Therapy / methods*
Esophageal Neoplasms / diagnosis,  pathology*
Fluorodeoxyglucose F18 / diagnostic use*,  pharmacokinetics
Middle Aged
Neoadjuvant Therapy / methods
Positron-Emission Tomography / methods*
ROC Curve
Treatment Outcome
Reg. No./Substance:
63503-12-8/Fluorodeoxyglucose F18
Comment In:
Eur J Nucl Med Mol Imaging. 2009 May;36(5):733-4   [PMID:  19225776 ]
Erratum In:
Eur J Nucl Med Mol Imaging. 2009 May;36(5):880
Note: Vallboehmer, Daniel [corrected to Vallböhmer, Daniel]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Bone marrow involvement in diffuse large B-cell lymphoma: correlation between FDG-PET uptake and typ...
Next Document:  Are "knife and fork" good enough for day case surgery of resistant tennis elbow?